Peter T Grant OAM

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow, et al.

Journal article  |  2020  |  ANNALS OF ONCOLOGY

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

T Sivakumaran, L Mileshkin, P Grant, L Na, A DeFazio, M Friedlander, A Obermair, PM Webb, G Au-Yeung

Journal article  |  2020  |  GYNECOLOGIC ONCOLOGY

OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women wi..

Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?

Vanessa L Beesley, Tanya L Ross, Nina Renhua Na, Tharani Sivakumaran, George Au-Yeung, Christina M Nagle, Anna deFazio, Peter Grant, Andreas Obermair, Michael Friedlander, Penelope Webb

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander

Journal article  |  2019  |  GYNECOLOGIC ONCOLOGY

OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran, Linda R Mileshkin, Peter T Grant, Michael Friedlander, Penelope M Webb, George Au-Yeung

Conference Proceedings  |  2018  |  JOURNAL OF CLINICAL ONCOLOGY

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

YC Lee, M Bressel, P Grant, P Russell, C Smith, S Picken, S Camm, BE Kiely, RL Milne, SA McLachlan, M Hickey, ML Friedlander, JL Hopper, KA Phillips

Journal article  |  2017  |  FAMILIAL CANCER

OBJECTIVES: The quality of risk-reducing salpingo-oophorectomy (RRSO) performed in Australasian women was previously reported to b..

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer

Anthony Bonaventura, Rachel L O'Connell, Cristina Mapagu, Philip J Beale, Orla M McNally, Linda R Mileshkin, Peter T Grant, Alison M Hadley, Jeffery CH Goh, Katrin M Sjoquist, Julie Martyn, Anna DeFazio, James Scurry, Michael L Friedlander

Journal article  |  2017  |  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

BACKGROUND: There is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. ..

Oral cyclophosphamide in recurrent ovarian cancer

Despina Handolias, Michael Quinn, Serene Foo, Linda Mileshkin, Peter Grant, Gaelle Dutu, Danny Rischin

Journal article  |  2016  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

AIMS: Cyclophosphamide was widely used as a single agent prior to the advent of platinum-based regimens for epithelial ovarian can..

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Paul Lr Mitchell, Michael A Quinn, Peter T Grant, David G Allen, Thomas W Jobling, Shane C White, Anne Zhao, Vaios Karanikas, Hilary Vaughan, Geoffrey Pietersz, Ian Fc McKenzie, Sharron E Gargosky, Bruce E Loveland

Journal article  |  2014  |  J Immunother Cancer

BACKGROUND: Mucin 1 antigen, highly expressed by epithelial ovarian cancer (EOC), is a potential target for immunotherapy. A previ..

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer

Tracey Edgell, G Martin-Roussety, G Barker, DJ Autelitano, D Allen, P Grant, GE Rice

Journal article  |  2010  |  JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

PURPOSE: The primary hypothesis to be tested in this study was that the diagnostic performance (as assessed by the area under the ..